{"id":"W2314401326","doi":"10.5414/cpp44180","title":"Comparative bioavailability of a generic capsule formulation of the reverse transcriptase inhibitor efavirenz and the innovator product","year":2006,"lang":"en","type":"article","venue":"International Journal of Clinical Pharmacology and Therapeutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"BioPhage Pharma (Canada)","funders":"","keywords":"Efavirenz; Bioequivalence; Reverse-transcriptase inhibitor; Pharmacokinetics; Capsule; Bioavailability; Cmax; Pharmacology; Crossover study; Medicine; Chemistry; Human immunodeficiency virus (HIV); Viral load; Virology; Biology; Antiretroviral therapy; Placebo","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008650151,0.00007887291,0.0003612689,0.00006044288,0.00002936014,0.000003850963,0.0000943691,0.00004870042,0.00002514739],"category_scores_gemma":[0.00004247788,0.00003909542,0.0001227375,0.0001077375,0.0005488383,0.00005484783,0.00002435526,0.000214775,3.471313e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001775056,"about_ca_system_score_gemma":0.0001435791,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006380212,"about_ca_topic_score_gemma":0.000002471613,"domain_scores_codex":[0.9985536,0.0002063648,0.0008794693,0.00008502272,0.0002165849,0.00005894795],"domain_scores_gemma":[0.9985532,0.0002789251,0.0005854343,0.00005904674,0.0004965737,0.00002684461],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02325942,0.005095925,0.7821904,0.0001351764,0.007670887,0.00004443007,0.004692708,0.00006400267,0.1420898,0.005720209,0.007815746,0.02122137],"study_design_scores_gemma":[0.04804144,0.0007980742,0.6434838,0.000181567,0.002513976,0.0002694972,0.0003339358,0.001393635,0.2306266,0.005260919,0.06689501,0.0002015535],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9852763,0.0009769098,0.00004560319,0.01252324,0.0008344757,0.0002400993,0.00001293188,0.000001720768,0.00008868452],"genre_scores_gemma":[0.9979945,0.000372009,0.0003519258,0.0007274066,0.0003302609,0.000002303224,0.000003017005,0.000003308818,0.0002153144],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1387066,"threshold_uncertainty_score":0.2022218,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06567932079286021,"score_gpt":0.4078633520262846,"score_spread":0.3421840312334244,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}